Mark J. Holdbrook is V.P. & Clinical Affairs at Tarsus Pharmaceuticals, Inc. (TARS). They have made 2 open-market trades across 1 company since 2023, most recently 2023-03-20.
CIK 0001827564
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 2 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| TARS | 3,389 | $231K |
Shares reported on the most recent Form 4, priced at the 2023-03-21 close.
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.